Preview

Rational Pharmacotherapy in Cardiology

Advanced search

NEBIVOLOL – ESPECIAL BETA-ADRENOBLOCKER

https://doi.org/10.20996/1819-6446-2010-6-2-220-228

Full Text:

Abstract

Translation and publication of the paper is performed with the permission of American College of Cardiology and under control of Society of Cardiology of the Russian Federation. Paper Műnzel T, Gori T. Nebivolol. The somewhat-different β-adrenergic receptor blocker was initially published in J Am Coll Cardiol 2009;54:1491–9 © 2009 by the American College of Cardiology Foundation.

About the Authors

T. Műnzel
The 2nd Medical Clinic of Cardiology and Angiology, Mainz
Germany
Langenbeckstrasse 1, Mainz, 55131


T. Gori
The 2nd Medical Clinic of Cardiology and Angiology, Mainz
Germany
Langenbeckstrasse 1, Mainz, 55131


References

1. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708–14.

2. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104: 2673– 8.

3. Gori T, Parker JD. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol 2008;52:251– 4.

4. Rozec B, Quang TT, Noireaud J, Gauthier C. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol 2006;147:699 –706.

5. Van Nueten L, De Cree J. Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heartrate and systolic blood pressure. Cardiovasc Drugs Ther 1998;12:339–44.

6. Xhonneux R, Wouters L, Reneman RS, Janssen PA. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. Eur J Pharmacol 1990;181:261–5.

7. Stoleru L, Wijns W, van Eyll C, Bouvy T, Van Nueten L, Pouleur H. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol. J Car￾diovasc Pharmacol 1993;22:183–90.

8. Cazzola M, Matera MG, Ruggeri P, et al. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration 2004;71: 159–64.

9. D’Agostino B, Gallelli L, Falciani M, et al. Nebivolol and airway responsiveness in the rabbit. Life Sci 2001;68:2159–68.

10. Brixius K, Bundkirchen A, Bolck B, Mehlhorn U, Schwinger RH. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001;133:1330–8.

11. Bundkirchen A, Brixius K, Bolck B, Mehlhorn U, Bloch W, Schwinger RH. Nebivolol, carvedilol and metoprolol do not influence cardiac Ca(2) sensitivity. Eur J Pharmacol 2001;422:175– 80.

12. Lu HR, Remeysen P, De Clerck F. Antiarrhythmic effects of nebivolol in experimental models in vivo. J Cardiovasc Pharmacol 1994;24:986–93.

13. Galetta F, Franzoni F, Magagna A, et al. Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother 2005;59:15–9.

14. Tuncer M, Fettser DV, Gunes Y, et al. Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension [in Russian]. Kardiologiia 2008;48:42–5.

15. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991;17:964 –9

16. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999;33:467–71.

17. Noda K, Oka M, Ma FH, Kitazawa S, Ukai Y, Toda N. Release of endothelial nitric oxide in coronary arteries by celiprolol, a beta(1)-adrenoceptor antagonist: possible clinical relevance. Eur J Pharmacol 2001;415:209 –16.

18. Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008;26:189 –202.

19. Hattori K, Yamanouchi D, Banno H, et al. Celiprolol reduces the intimal thickening of autogenous vein grafts via an enhancement of nitric oxide function through an inhibition of superoxide production. J Vasc Surg 2007;46:116 –23.

20. Kobayashi N, Mori Y, Nakano S, Tsubokou Y, Shirataki H, Matsuoka H. Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardialremodeling in deoxycorticosterone acetatesalt hypertensive rats. J Hypertens 2001;19:795– 801.

21. Ladage D, Brixius K, Hoyer H, et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 2006;33:720–4.

22. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677– 84.

23. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005;112:1198 –205.

24. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Thirdgeneration beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747–52.

25. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004;110:948–54.

26. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NOdependent mechanism. J Pharmacol Exp Ther 1995;274:1067–71.

27. Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999;48:460 –3.

28. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199 –204.

29. Burger W, Hampel C, Kaltenbach M, et al. Effect of atenolol and celiprolol on acetylcholine-induced coronary vasomotion in coronary artery disease. Am J Cardiol 2000;85:172–7.

30. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001;104:511– 4.

31. Schmidt AC, Flick B, Jahn E, Bramlage P. Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers. Vasc Health Risk Manag 2008;4:909 –15.

32. Korkmaz H, Karaca I, Koc M, Onalan O, Yilmaz M, Bilen MN. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. Endothelium 2008;15:149-55.

33. Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flowmediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005;19: 277- 81.

34. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003;23:615–21.

35. Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006;48:677– 84.

36. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112: 3795-801.

37. Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838–44.

38. Garbin U, Pasini AF, Stranieri C, Manfro S, Boccioletti V, Cominacini L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 2007;56:515–21.

39. Falciani M, Rinaldi B, D’Agostino B, et al. Effects of nebivolol on human platelet aggregation. J Car￾diovasc Pharmacol 2001;38:922–9.

40. Celik T, Iyisoy A, Kardesoglu E, Fici F. The anti-inflammatory effects of nebivolol in human coronary smooth muscle cells: clinical implications. Int J Cardiol 2009;133:415– 6.

41. Tarighi B, Kurum T, Demir M, Azcan SN. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients. Can J Cardiol 2007;23:651–5.

42. Vyssoulis GP, Marinakis AG, Aznaouridis KA, et al. The impact of third-generation beta-blocker an￾tihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am J Hypertens 2004;17:582–9.

43. Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36:S401–3.

44. Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001;49:430 –9.

45. Wolf SC, Sauter G, Jobst J, Kempf VA, Risler T, Brehm BR. Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. Int J Cardiol 2008;125:4 –10.

46. Wolf SC, Sauter G, Preyer M, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007;19: 129-36.

47. Ignarro LJ, Sisodia M, Trinh K, et al. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002;7:83–90.

48. Garbin U, Fratta Pasini A, Stranieri C, et al. Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm 2008;2008:367590.

49. Renna N, Risler N, Cruzado M, Gonzalez S, Lama C, Miatello RM. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance. Cell Mol Biol (Noisy-le-grand) 2005;51:531–7.

50. de Nigris F, Mancini FP, Balestrieri ML, et al. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide 2008;19:57– 63.

51. Cleophas TJ, Agrawal R, Lichtenthal A, Makel W, Fici F. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. Am J Ther 2006;13:192–7.

52. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-tomoderate essential hypertension:results of a double-blind randomized multicentre trial. Blood Press Suppl 2003;2:35– 40.

53. Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina AC. Nebivolol vs amlodipine as first￾line treatment of essential arterial hypertension in the elderly. Blood Press 2002;11:182- 8.

54. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998;12:135– 40.

55. Ambrosioni E, Bacchelli S, Esposti DD, Borghi C. Beta-blockade in hypertension and congestive heart failure. J Cardiovasc Pharmacol 2001;38 Suppl 3:S25–31.

56. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blockerinduced heart rate lowering and car￾dioprotection in hypertension. J Am Coll Cardiol 2008;52:1482–9.

57. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351–7.

58. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular func￾tion of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Car￾diol 2003;92:344–8.

59. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094 –100.

60. Uhlir O, Dvorak I, Gregor P, et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail 1997;3:271– 6.

61. ZanchettiA. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004;1:17–32.

62. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and ar￾terial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5:621–7.

63. Brune S, Schmidt T, Tebbe U, Kreuzer H. Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure. Angiology 1990;41:696 –701.

64. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPER￾NICUS) study. Circulation 2002;106:2194–9.

65. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlledrelease metoprolol on total mor￾tality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295–302.

66. Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with or with￾out systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006;27:562– 8.

67. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–25.

68. Vandeplassche G, Lu HR, Wouters L, Flameng W, Borgers M. Normothermic ischemic cardiac arrest in the isolated working rabbit heart: effects of dl-nebivolol and atenolol. Basic Res Cardiol 1991;86:21–31.

69. Van Bortel LM, van Baak MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drugs Ther 1992;6:239–47.

70. Galderisi M, D’Errico A. Beta-blockers and coronary flow reserve: the importance of a vasodilatory action. Drugs 2008;68:579 –90.

71. Cazzola M, Noschese P, D’Amato G, Matera MG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest 2002;121:230–41.

72. Cazzola M, Noschese P, D’Amato M, D’Amato G. Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. Chest 2000;118:1322- 6.

73. Zuber ME, P. Changes in peak respiratory flow and quality of life during nebivolol therapy. Heart Drug 2004;4:103– 8.

74. Boydak B, Nalbantgil S, Fici F, et al. A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Investig 2005;25:409–16.

75. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007;34:327–31.

76. Ambrosioni E, Borghi C. Tolerability of Nebivolol in head-to-head clinical trial versus other cardioselective beta-blockers in the treatment of hypertension. High Blood Pree Cardiovasc Prev 2005;12:27–35.

77. Ruf G, Trenk D, Jahnchen E, Roskamm H. Determination of the anti-ischemic activity of nebivolol in comparison with atenolol. Int J Cardiol 1994;43:279–85.

78. Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med 2008;168:2415–21.

79. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.


For citation:


Műnzel T., Gori T. NEBIVOLOL – ESPECIAL BETA-ADRENOBLOCKER. Rational Pharmacotherapy in Cardiology. 2010;6(2):220-228. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-2-220-228

Views: 563


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)